FOR IMMEDIATE RELEASE

SOMANETICS AND SCIOS CO-SPONSOR CONGESTIVE HEART FAILURE PROGRAM AT TEXAS HEART INSTITUTE


The one-day program featured topics relating to Surgical Ventricular Restoration, SVR, with Somanetics’ CorRestore™ System, and the treatment of congestive heart failure with Scios’ drug Natrecor®. The program was taught by Texas Heart Institute and St. Luke’s Episcopal Hospital faculty and visiting faculty, and included a wet lab to provide a hands-on demonstration of the SVR operative technique. More than 60 medical professionals attended the program.

“Education is the cornerstone of developing new markets for novel drugs and medical devices and we have a common interest with Scios Inc. in the field of congestive heart failure,” said Bruce Barrett, Somanetics’ president and CEO. “Co-sponsoring programs gives participating clinicians a broader educational experience and allows us to afford to conduct more educational forums.”

Scios also is co-sponsoring a program with Somanetics at The Ohio State University Medical School on March 13. The program, “Surgical Ventricular Restoration and Other Advances in Congestive Heart Failure Treatment,” is expected to draw approximately 65 cardiac surgeons, cardiologists, CHF nurses and others who diagnose and treat CHF patients.

Somanetics also will sponsor “Surgical Ventricular Restoration, A Surgical Alternative for Severe Congestive Heart Failure Patients,” presented by Westchester Medical Center and New York Medical College, on March 8. With that program, New York Medical College becomes Somanetics’ fourth center of excellence for teaching physicians and others who treat congestive heart failure patients about SVR.

(more)
Scios Inc. is a biopharmaceutical company developing novel drugs for the potential treatment of cardiovascular and inflammatory diseases. The company discovered, developed and markets Natrecor® (Nesiritide), the first new treatment for acute heart failure in more than a decade. Scios has a growing pipeline, including SCIO-469, one of the first oral p38 kinase inhibitors in clinical trials, being studied for the potential treatment of rheumatoid arthritis. Scios’ disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to design small molecule compounds for large markets with unmet medical needs. Scios’ web site address is http://www.sciosinc.com.

Somanetics Corporation is a medical device company that develops and markets two medical devices focused on the cardiac surgery market. The CorRestore System is used in cardiac repair and reconstruction, including Surgical Ventricular Restoration, a surgical treatment for certain types of severe congestive heart failure. The INVOS Cerebral Oximeter is a patient monitoring system that monitors changes in the blood oxygen level in the brain, helping medical professionals to identify brain blood oxygen imbalances and take corrective action to prevent neurological injury related to surgery. Somanetics’ web site address is http://www.somanetics.com.

###